Literature DB >> 21542846

Immuno- and antiinflammatory therapies in epileptic disorders.

Çiğdem Özkara1, Federico Vigevano.   

Abstract

Several experimental and clinical studies demonstrated an immunologic basis for different forms of epilepsy. A wide range of immune abnormalities have been reported suggesting the existence of various subtypes of epileptic syndromes with different immunopathogenetic mechanisms. This evidence gives rise to the development of immunologic and immunomodulatory treatments such as usage of steroids, plasmapheresis, and intravenous immunoglobulins, which will be discussed briefly in this article. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21542846     DOI: 10.1111/j.1528-1167.2011.03036.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy.

Authors:  Maria Carmela Pera; Giovanna Randazzo; Silvia Masnada; Serena Donetti Dontin; Valentina De Giorgis; Umberto Balottin; Pierangelo Veggiotti
Journal:  Funct Neurol       Date:  2015 Jul-Sep

3.  Neuroinflammatory Nexus of Pediatric Epilepsy.

Authors:  Shruti Bagla; Alan A Dombkowski
Journal:  J Pediatr Epilepsy       Date:  2018-09-03

Review 4.  Maternal immune activation and abnormal brain development across CNS disorders.

Authors:  Irene Knuesel; Laurie Chicha; Markus Britschgi; Scott A Schobel; Michael Bodmer; Jessica A Hellings; Stephen Toovey; Eric P Prinssen
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

5.  [Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: experience with six pediatric patients. Potential efficacy of methotrexate].

Authors:  Antonio Bravo-Oro; Carlos Abud-Mendoza; Arturo Quezada-Corona; Josep Dalmau; Verónica Campos-Guevara
Journal:  Rev Neurol       Date:  2013-11-01       Impact factor: 0.870

6.  Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study.

Authors:  Yi-Chien Lee; Yun-Jhong Huang; Miao-Chiu Hung; Sheng-Che Hung; Chih-Yen Hsiao; Hui-Ling Cho; Li-Fen Lai; Show-Hwa Tong; Jann-Tay Wang
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

7.  Follow-Up of Peripheral IL-1β and IL-6 and Relation with Apoptotic Death in Drug-Resistant Temporal Lobe Epilepsy Patients Submitted to Surgery.

Authors:  Lourdes Lorigados Pedre; Lilia M Morales Chacón; Nancy Pavón Fuentes; María de Los A Robinson Agramonte; Teresa Serrano Sánchez; Rachel M Cruz-Xenes; Mei-Li Díaz Hung; Bárbara Estupiñán Díaz; Margarita M Báez Martín; Sandra Orozco-Suárez
Journal:  Behav Sci (Basel)       Date:  2018-02-05

8.  Tumor necrosis factor-α and interleukin-6 concentrations in cerebrospinal fluid of dogs after seizures.

Authors:  Y Merbl; A Sommer; O Chai; I Aroch; G Zimmerman; A Friedman; H Soreq; M H Shamir
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

9.  Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China.

Authors:  Xinyue Zhang; Yue Lang; Lichao Sun; Weiguanliu Zhang; Weihong Lin; Li Cui
Journal:  BMC Neurol       Date:  2020-01-03       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.